A small case–control study (Goktas et al, 2005) indicates that plasma adiponectin levels are significantly lower in subjects with prostate cancer than in subjects with benign prostatic hyperplasia or in normal healthy controls. This evidence concerns the gene ADIPOQ and Familial prostate cancer.